Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Research & Development: 2022-2025

Historic Research & Development for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $65.8 million.

  • Praxis Precision Medicines' Research & Development rose 57.10% to $65.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.9 million, marking a year-over-year increase of 114.73%. This contributed to the annual value of $152.4 million for FY2024, which is 75.66% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Research & Development stood at $65.8 million, which was up 4.43% from $63.0 million recorded in Q2 2025.
  • Over the past 5 years, Praxis Precision Medicines' Research & Development peaked at $65.8 million during Q3 2025, and registered a low of $17.3 million during Q3 2023.
  • Over the past 3 years, Praxis Precision Medicines' median Research & Development value was $27.3 million (recorded in 2024), while the average stood at $39.0 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' Research & Development plummeted by 51.56% in 2023, and later surged by 206.11% in 2024.
  • Quarterly analysis of 4 years shows Praxis Precision Medicines' Research & Development stood at $28.3 million in 2022, then crashed by 35.09% to $18.4 million in 2023, then skyrocketed by 206.11% to $56.3 million in 2024, then skyrocketed by 57.10% to $65.8 million in 2025.
  • Its Research & Development stands at $65.8 million for Q3 2025, versus $63.0 million for Q2 2025 and $60.8 million for Q1 2025.